John K. Whisnant, Jr, MD
John Whisnant is available to contribute biotechnology and pharmaceutical experience to drug development projects. He brings excellent training in medicine (MD Wake Forest Univ., Amer Board of Pediatrics) and science (NIH and Duke, Immunology, ABAI), and he has continued to grow with rich opportunities in the best of R&D groups, and with great mentors at the right times (Wellcome to 1987, DuPont to 1991, Fujisawa 1992, and Novo Nordisk to 2002).
He applies medicine and science to business goals and processes, having learned at Ivax (1992-1995) and more recently in directing Coley's Development during its licensing and IPO successes with oligodeoxynucleotides.
Dr. Whisnant is prepared to help clients with new products or with projects that need support, expansion or evaluation. Areas of particular interest include the biological therapies of cancer, biotechnology products including interferons and recombinant proteins, cancer therapy strategies, diabetes therapies (OHA's, insulins, NCE's), all phases of clinical trials including safety issues, drug delivery including generics, and regulatory strategies/plans and documentation.
Leadership List
Officers
G. Alexander Fleming, MD
Founder and Executive Chairman
Thomas Seoh, J.D.
President and Chief Executive Officer
Brian Oscherwitz, MBA, PMP
Chief Operating Officer
Clinical Development
Ramachandra (Ram) G. Naik, M.D.
Regulatory Strategy and Operations
Biostatistics
EU Regulatory
Clinical Operations/Project Management
Julie Waltz Gerlach, B.S.N., M.P.H., R.A.C.
Pre-Clinical
CMC, Formulation/Process Development & Sourcing
Medical Device
QA/QC
Medical Writing/Electronic Submissions
Kristi Hultberg, B.S.
Botanicals
Government Relations and Public Affairs
Defense & National Security Practice
Commercialization and Business & Corporate Strategy
